AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

Tarek Samad appointed EVP, Head of Research & Development at Lundbeck

VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head...

Helus Pharma™ Announces US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on...

CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea’s Hub for Pharma, Biopharma, and Health Innovation

SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at COEX, Seoul,...

Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi appoints Paulo Fontoura as Global Head of R&D

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology

STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and...

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a...

FDA Clears PanopticAI’s Contactless Respiratory Rate Measurement

Following the startup's first FDA 510 (k) clearance for its contactless pulse rate monitoring, PanopticAI has now secured a second one for respiratory rate...

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

FDA Approves Labeled Strength Update of TWIRLA® (levonorgestrel/ethinyl estradiol) Birth Control Patch

FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) -- Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women’s health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system. The new labeled strength will begin to appear on the market in September or October of 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers